Patents Examined by Fozia M Hamud
-
Patent number: 7514536Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: April 7, 2009Assignee: ZymoGenetics, Inc.Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7507557Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: April 5, 2005Date of Patent: March 24, 2009Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Timothy A. Stewart, William I. Wood
-
Patent number: 7498151Abstract: The invention provides methods to identify polymorphisms at the human TLR4 locus, as well as methods to identify individuals at risk of indications that increase their morbidity and mortality.Type: GrantFiled: September 7, 2006Date of Patent: March 3, 2009Assignee: University of Iowa Research FoundationInventors: David A. Schwartz, Brian C. Schutte
-
Patent number: 7495078Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 16, 2006Date of Patent: February 24, 2009Assignee: ZymoGenetics, Inc.Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7495080Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: GrantFiled: October 20, 2006Date of Patent: February 24, 2009Assignee: ZymoGenetics, Inc.Inventors: Cindy A. Sprecher, Scott R. Presnell, Zeren Gao, Theodore E. Whitmore, Joseph L. Kuijper, Mark F. Maurer
-
Patent number: 7494804Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.Type: GrantFiled: January 21, 2003Date of Patent: February 24, 2009Assignee: ZymoGenetics, Inc.Inventors: Cindy A. Sprecher, Zeren Gao, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Scott R. Presnell, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
-
Patent number: 7495077Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 13, 2006Date of Patent: February 24, 2009Assignee: ZymoGenetics, Inc.Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7495079Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 16, 2006Date of Patent: February 24, 2009Assignee: ZymoGenetics, Inc.Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7485432Abstract: Methods of identifying a compound that selectively modulates at least one TLR-mediated cellular activity are disclosed. Generally, the methods include identifying a compound as a compound that selectively modulates at least one TLR-mediated cellular activity if the compound modulates one TLR-mediated cellular activity to a different extent than it modulates a second TLR-mediated cellular activity. Compounds so identified and pharmaceutical compositions including such compounds are also disclosed. Methods of selectively modulating immune cells and methods of treating certain conditions are also provided. Such methods include administering to cells or a subject a compound that selectively modulates a TLR-mediated cellular activity.Type: GrantFiled: February 27, 2004Date of Patent: February 3, 2009Assignee: 3M Innovative Properties CompanyInventors: Jason R. Fink, Keith B. Gorden, Kevin S. Gorski, Shalley K. Gupta, Xiaohong Qiu, John P. Vasilakos
-
Patent number: 7485702Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 16, 2006Date of Patent: February 3, 2009Assignee: ZymoGenetics, Inc.Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7485701Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 13, 2006Date of Patent: February 3, 2009Assignee: ZymoGenetics, Inc.Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7479542Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 16, 2006Date of Patent: January 20, 2009Assignee: ZymoGenetics, Inc.Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7473537Abstract: The invention relates to nucleotides and amino acid sequences encoding glucagon-like peptide 2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications.Type: GrantFiled: December 15, 1997Date of Patent: January 6, 2009Assignee: NPS Pharmaceuticals, Inc.Inventors: Donald G. Munroe, Ashwani K. Gupta, Tejal B. Vyas, Kirk McCallum, Ermi Fan
-
Patent number: 7468423Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 13, 2006Date of Patent: December 23, 2008Assignee: ZymoGenetics, Inc.Inventors: Lowell J. Brady, Kevin M. Klucher, Chung-leung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7465450Abstract: Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.Type: GrantFiled: October 27, 2006Date of Patent: December 16, 2008Assignee: Immunex CorporationInventor: John D. Pluenneke
-
Patent number: 7459528Abstract: Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.Type: GrantFiled: October 28, 2005Date of Patent: December 2, 2008Assignee: Immunex CorporationInventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
-
Patent number: 7456256Abstract: The present invention provides novel polynucleotides encoding BGS-2, 3, and 4 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides of the present invention. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-2, 3, and 4 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.Type: GrantFiled: March 21, 2007Date of Patent: November 25, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Shujian Wu, Stanley R. Krystek, Jr., Liana M. Lee, John N. Feder, Janet D. Cheng
-
Patent number: 7445779Abstract: Provided are cytokines and methods of modulating activity of the immune system using cytokine agonists and antagonists. Also provided are methods of treatment of immune and proliferative disorders.Type: GrantFiled: December 18, 2003Date of Patent: November 4, 2008Assignee: Schering CorporationInventors: Rene De Waal Malefyt, Marilyn Travis, Elena Vaisberg
-
Patent number: 7445905Abstract: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: January 26, 2007Date of Patent: November 4, 2008Assignee: Genentech, Inc.Inventors: Austin L. Gurney, Sudeepta Aggarwal, Ming-Hong Xie, Ellen M. Maruoka, Jessica S. Foster, Audrey Goddard, William I. Wood
-
Patent number: 7446173Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: GrantFiled: March 16, 2004Date of Patent: November 4, 2008Assignee: Biogen Idec MA Inc.Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman